Key result
The LLR3 rotavirus vaccine provided 56.6% vaccine efficacy (95% CI 50.7-61.8) against rotavirus gastroenteritis of any severity in healthy Chinese infants.
Why the study?
To assess the efficacy, immunogenicity, and safety of a novel trivalent live human-lamb reassortant rotavirus vaccine (LLR3) against rotavirus gastroenteritis in healthy Chinese infants.
Does 3 oral doses of LLR3 vaccine prevent rotavirus gastroenteritis in healthy Chinese infants?
RCT
Double-blind
1:1
Yes
Does 3 oral doses of LLR3 vaccine prevent rotavirus gastroenteritis in healthy Chinese infants?
Effect estimate: VE 56.6% (95% CI 50.7-61.8)
The LLR3 rotavirus vaccine provides substantial protection against rotavirus gastroenteritis of any severity and severe cases in Chinese infants, with a favorable safety profile.
Supports LLR3 use in Chinese infants; extends RCT evidence for rotavirus vaccination to this population.
BACKGROUND: A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy, immunogenicity and safety of a novel trivalent live human-lamb reassortant rotavirus vaccine (LLR3) against rotavirus gastroenteritis (RVGE). METHODS: Healthy children aged 6-13 weeks were enrolled and randomized (1:1) to either 3 oral doses of LLR3 or placebo according to a 0, 1, 2 month schedule. The objectives were to evaluate vaccine efficacy (VE) against RVGE of any-severity, severe RVGE (sRVGE) and inpatient caused by rotavirus serotypes contained in the vaccine and not contained in the vaccine after the third dose. Immunogenicity was also assayed in a subgroup. All adverse events (AEs) were collected from 30 min after each dose for immediate reaction, even to the entire study period, including the serious AEs (SAEs) and intussusception. RESULTS: VE against RVGE of any-severity, sRVGE and inpatient caused by any serotype was 56.6% (95% CI: 50.7, 61.8), 70.3% (95% CI: 60.6, 77.6) and 74.0% (95% CI: 57.5, 84.1) respectively. VE against RVGE of any-severity, sRVGE caused by serotypes not contained in vaccine were 54.2% (95% CI: 47.5, 60.1) and 70.4% (95% CI: 60.4, 77.9). The rate of seroconversion and four-fold increase of rotavirus serotype G2-, G3-, and G4-specific IgA is 60.8%, 58.0%, and 60.6% in vaccine group, which was higher than 21.35%, 22.7%, and 23.1% in placebo group (p < 0.0001 for G2, G3, G4), as well as the Geometric Mean Titer (GMT). Through the entire trial, 65.91% and 67.79% of participants reported at least one AE, and 0.02% and 0.02% reported SAEs in the vaccine and placebo groups, respectively. Two intussusception cases were reported both in vaccine and placebo group. CONCLUSIONS: In Chinese infants, LLR3 provided a substantial protection against RVGE of any-severity, sRVGE and inpatient caused by any serotype, and showed well immunogenicity and safety.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2020) conducted an RCT in Rotavirus gastroenteritis (RVGE). Trivalent live human-lamb reassortant rotavirus vaccine (LLR3) vs. Placebo was evaluated on Rotavirus gastroenteritis (RVGE) of any-severity caused by any serotype (VE 56.6%, 95% CI 50.7-61.8). The LLR3 rotavirus vaccine provided 56.6% vaccine efficacy (95% CI 50.7-61.8) against rotavirus gastroenteritis of any severity in healthy Chinese infants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: